Pozen's Value Proposition For An Affordable Innovative Medicine
This article was originally published in The Pink Sheet Daily
Executive Summary
Its value proposition for its Phase III cardiovascular drug flies in the face of traditional market strategy, but Pozen argues it has a viable approach to affordable innovation.